Evidence map›Paper›PMID 21523499›Full record

Trial reportWorld journal of surgery2011

NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.

Klaus Sahora, Irene Kuehrer, Martin Schindl, Claus Koelblinger, Peter Goetzinger, Michael Gnant

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in World journal of surgery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Is Complete Pathologic Response in Pancreatic Cancer Overestimated? A Systematic Review of Prospective Studies.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2015
    Trial
  7. Review
  8. Article
  9. Article
  10. Evolving treatment landscape for early and advanced pancreatic cancer.World journal of gastrointestinal oncology · 2017
    Review
  11. Article
  12. Neoadjuvant therapy for pancreatic cancer: an ongoing debate.Therapeutic advances in gastroenterology · 2016
    Article
  13. Review
  14. Article
  15. Advances in chemotherapy for pancreatic cancer.Indian journal of surgical oncology · 2015
    Review
  16. Review
  17. Review
  18. Neoadjuvant strategies for pancreatic cancer.World journal of gastroenterology · 2014
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Klaus SahoraDepartment of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Irene Kuehrer
Martin Schindl
Claus Koelblinger
Peter Goetzinger
Michael Gnant

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbout 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to assess the rate of complete radical resection and overall survival.

methodsGemcitabine (900 mg/m2) and docetaxel (35 mg/m2) were given on days 1, 8, and 15 of a 28-day cycle. Two cycles were administered for a preoperative treatment duration of 8 weeks. Patients experiencing tumor regression or stable disease and improved performance status subsequently underwent surgical exploration and pancreatic resection, if feasible. All patients were followed postoperatively to assess long-term survival.

resultsA total of 25 patients were eligible and included in the intent-to-treat and evaluable population. Thirteen patients had unresectable disease at inclusion and 12 patients had borderline resectable pancreatic cancer. Finally, 8 of 25 (32%) patients underwent resection after neoadjuvant chemotherapy; 7 (87%) of these patients had R0 resection. The median overall survival of patients who underwent resection was 16 months (95% confidence interval [CI], 8-24 months) compared to 12 months (95% CI, 8-16 months) for those without resection (p=0.276). The median recurrence-free survival rate after resection was 12 months (95% CI, 2-21 months).

conclusionsNeoGemTax was safe and resection was feasible in a number of patients after systemic neoadjuvant treatment. Further randomized clinical trials are needed to identify novel multimodal regimens that would be able to increase the percentage of patients undergoing curative pancreatic cancer surgery despite advanced tumor stage at the time of diagnosis.

Indexed as

AdenocarcinomaAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDocetaxelFemaleGemcitabineHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPancreatic NeoplasmsProspective StudiesTaxoidsDeoxycytidineDocetaxelGemcitabineTaxoids

Identifiers

PMID21523499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.